Vyome Holdings reports Q2 2026 results, advances VT-1953 malodor program

Vyome Holdings, Inc. reported second-quarter 2026 results on August 25, 2026, centered on its lead candidate VT-1953, a topical gel being developed for malignant fungating wounds. The company said in March 2026, it submitted a pre-IND briefing package to the FDA that included its proposed pivotal clinical study strategy for the treatment of malodor and other symptoms associated with malignant fungating wounds.¹ During the second quarter of 2026, the company received the FDA's written response on the proposed clinical development program.¹ Vyome said it is incorporating the FDA's feedback, preparing the appropriate supporting package, and plans to continue its engagement with the FDA through a Type C meeting to further advance the clinical development program.¹

On clinical data, the company said Phase 2 data presented this year demonstrated statistically significant improvements in malodor, the patient-reported impact of malodor on daily life, and lesion pain, with no treatment-emergent adverse events reported.¹ That data was presented at the American Association for Cancer Research (AACR).¹

Vyome also disclosed pipeline additions and intellectual property news. It said it signed an agreement with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets designed for higher selectivity to potentially treat autoimmune and inflammatory conditions.¹ Separately, the company said it received a granted Chinese patent covering formulation and therapeutic use claims related to VB-1953 topical gel program for treating inflammatory acne¹, a designation distinct from the VT-1953 lead program described elsewhere in the release.

On finances, Vyome reported cash and cash equivalents of approximately $7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025¹, and said it continues to maintain a clean capital structure with no debt, no preferred stock, and no toxic financing instruments.¹